Overexpression of 15-lipoxygenase-1 in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via downregulation of vascular endothelial growth factor-a expression

Molecular Vision

Volumn 18, Issue , 2012, Pages 2847-2859

  Li, Zhi ^a,b   He, Tao ^a   Du, Ke ^b   Xing, Yi Qiao ^a   Yan, Ying ^c   Chen, Zhen ^a   Zhang, Hao ^b   Shen, Yin ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b Xiangyang Center Hospital   (China)

^c WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; GREEN FLUORESCENT PROTEIN; VASCULOTROPIN A;

15 LIPOXYGENASE 1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; GENE FUNCTION; GENE OVEREXPRESSION; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RETINA BIPOLAR GANGLION CELL; RETINA NEOVASCULARIZATION; RETINOPATHY; WESTERN BLOTTING;

ANIMALS; ARACHIDONATE 15-LIPOXYGENASE; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; MICE; MICE, INBRED C57BL; OXYGEN; RETINA; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; TRANSDUCTION, GENETIC; TRANSGENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84871096928     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997; 22:251-6. [PMID: 9255066].
2. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997; 13:37-50. [PMID: 9134347].
3. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999; 274:23679-82. [PMID: 10446122].
4. Kuhn H, Chaitidis P, Roffeis J, Walther M. Arachidonic Acid metabolites in the cardiovascular system: the role of lipoxygenase isoforms in atherogenesis with particular emphasis on vascular remodeling. J Cardiovasc Pharmacol 2007; 50:609-20. [PMID: 18091576].
5. Kuhn H, Thiele BJ. The diversity of the lipoxygenase family. Many sequence data but little information on biological significance. FEBS Lett 1999; 449:7-11. [PMID: 10225417].
6. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci USA 1997; 94:6148-52. [PMID: 9177185].
7. Fleming J, Thiele BJ, Chester J, O'Prey J, Janetzki S, Aitken A, Anton IA, Rapoport SM, Harrison PR. The complete sequence of the rabbit erythroid cell-specific 15-lipoxygenase mRNA: comparison of the predicted amino acid sequence of the erythrocyte lipoxygenase with other lipoxygenases. Gene 1989; 79:181-8. [PMID: 2777088].
8. Kühn H, O'Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res 2006; 45:334-56. [PMID: 16678271].
9. Funk CD. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta 1996; 1304:65-84. [PMID: 8944751].
10. Shappell SB, Boeglin WE, Olson SJ, Kasper S, Brash AR. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 1999; 155:235-45. [PMID: 10393855].
11. Fürstenberger G, Krieg P, Muller-Decker K, Habenicht AJ. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis. Int J Cancer 2006; 119:2247-54. [PMID: 16921484].
12. Kühn H, Walther M, Kuban RJ. Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. Prostaglandins Other Lipid Mediat 2002; 68-69:263-90. [PMID: 12432923].
13. Kühn H, Romisch I, Belkner J. The role of lipoxygenase-isoforms in atherogenesis. Mol Nutr Food Res 2005; 49:1014-29. [PMID: 16270276].
14. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999; 103:1597-604. [PMID: 10359569].
15. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, Kühn H, Guevara NV, Chan L. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1996; 98:2201-8. [PMID: 8941635].
16. Zuo X, Wu Y, Morris JS, Stimmel JB, Leesnitzer LM, Fischer SM, Lippman SM, Shureiqi I. Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity. Oncogene 2006; 25:1225-41. [PMID: 16288226].
17. Sasaki T, Fujii K, Yoshida K, Shimura H, Sasahira T, Ohmori H, Kuniyasu H. Peritoneal metastasis inhibition by linoleic acid with activation of PPARgamma in human gastrointestinal cancer cells. Virchows Arch 2006; 448:422-7. [PMID: 16362414].
18. Sarayba MA, Li L, Tungsiripat T, Liu NH, Sweet PM, Patel AJ, Osann KE, Chittiboyina A, Benson SC, Pershadsingh HA, Chuck RS. Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. Exp Eye Res 2005; 80:435-42. [PMID: 15721625].
19. Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, Hsueh WA, Ryan SJ, Law RE, Hinton DR. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 2000; 41:2309-17. [PMID: 10892878].
20. Soumya SJ, Binu S, Helen A, Anil Kumar K, Reddanna P, Sudhakaran PR. Effect of 15-lipoxygenase metabolites on angiogenesis: 15(S)-HPETE is angiostatic and 15(S)-HETE is angiogenic. Inflamm Res 2012; 61:707-18. [PMID: 22450700].
21. Mochizuki N, Kwon YG. 15-lipoxygenase-1 in the vasculature: expanding roles in angiogenesis. Circ Res 2008; 102:143-5. [PMID: 18239141].
22. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25:111-8. [PMID: 15689799].
23. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22:1-29. [PMID: 12597922].
24. Wang X, Wang G, Wang Y. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2009; 148:883-9. [PMID: 19837381].
25. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-7. [PMID: 7526212].
26. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92:905-9. [PMID: 7846076].
27. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 2001; 489:270-6. [PMID: 11165263].
28. Zhang SX, Wang JJ, Gao G, Parke K, Ma JX. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 2006; 37:1-12. [PMID: 16901919].
29. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95:11709-14. [PMID: 9751730].
30. Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 1999; 237:41-57. [PMID: 9893345].
31. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999; 237:1-30. [PMID: 9893343].
32. Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 1999; 237:31-40. [PMID: 9893344].
33. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008; 27:331-71. [PMID: 18653375].
34. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581-611. [PMID: 15294883].
35. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35:101-11. [PMID: 7507904].
36. Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 2001; 44:757-65. [PMID: 11440369].
37. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearlman J, Mori K, Yang HS, Zack DJ, Ettyreddy D, Brough DE, Wei LL, Campochiaro PA. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001; 188:253-63. [PMID: 11424092].
38. Zhong X, Huang H, Shen J, Zacchigna S, Zentilin L, Giacca M, Vinores SA. Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation. Mol Vis 2011; 17:492-507. [PMID: 21364963].
39. Ke JB, Zhong YM. Expression of somatostatin receptor subtype 5 in rat retinal amacrine cells. Neuroscience 2007; 144:1025-32. [PMID: 17156933].
40. Park K, Chen Y, Hu Y, Mayo AS, Kompella UB, Longeras R, Ma JX. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes 2009; 58:1902-13. [PMID: 19491211].
41. Zhang Q, Zhang J, Guan Y, Zhang S, Zhu C, Xu GT, Wang L. Suppression of retinal neovascularization by the iNOS inhibitor Aminoguanidine in mice of oxygen-induced retinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247:919-27. [PMID: 19301028].
42. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008; 118:526-33. [PMID: 18219389].
43. Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, Sapieha P, Stahl A, Willett KL, Smith LE. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc 2009; 4:1565-73. [PMID: 19816419].
44. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR andthe 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8.
45. Smith LE. Pathogenesis of retinopathy of prematurity. Acta Paediatr Suppl 2002; 91:26-8. [PMID: 12200894].
46. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007; 10:141-8. [PMID: 17372853].
47. Hernández C, Simo R. Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice. Expert Opin Investig Drugs 2007; 16:1209-26. [PMID: 17685870].
48. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26:275-8. [PMID: 16508426].
49. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142:155-8. [PMID: 16815267].
50. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248:915-30. [PMID: 20174816].
51. Kelavkar UP, Nixon JB, Cohen C, Dillehay D, Eling TE, Badr KF. Overexpression of 15-lipoxygenase-1 in PC-3 human prostate cancer cells increases tumorigenesis. Carcinogenesis 2001; 22:1765-73. [PMID: 11698337].
52. Harats D, Ben-Shushan D, Cohen H, Gonen A, Barshack I, Goldberg I, Greenberger S, Hodish I, Harari A, Varda-Bloom N, Levanon K, Grossman E, Chaitidis P, Kühn H, Shaish A. Inhibition of carcinogenesis in transgenic mouse models over-expressing 15-lipoxygenase in the vascular wall under the control of murine preproendothelin-1 promoter. Cancer Lett 2005; 229:127-34. [PMID: 16157225].
53. Viita H, Markkanen J, Eriksson E, Nurminen M, Kinnunen K, Babu M, Heikura T, Turpeinen S, Laidinen S, Takalo T, Ylä-Herttuala S. 15-lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression. Circ Res 2008; 102:177-84. [PMID: 17991885].
54. Viita H, Kinnunen K, Eriksson E, Lähteenvuo J, Babu M, Kalesnykas G, Heikura T, Laidinen S, Takalo T, Ylä-Herttuala S. Intravitreal adenoviral 15-lipoxygenase-1 gene transfer prevents vascular endothelial growth factor A-induced neovascularization in rabbit eyes. Hum Gene Ther 2009; 20:1679-86. [PMID: 19694557].
55. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996; 114:1219-28. [PMID: 8859081].
56. Claxton S, Fruttiger M. Role of arteries in oxygen induced vaso-obliteration. Exp Eye Res 2003; 77:305-11. [PMID: 12907163].
57. Gu X, El-Remessy AB, Brooks SE, Al-Shabrawey M, Tsai NT, Caldwell RB. Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite. Am J Physiol Cell Physiol 2003; 285:C546-54. [PMID: 12736139].
58. Kinnunen K, Korpisalo P, Rissanen TT, Heikura T, Viita H, Uusitalo H, Ylä-Herttuala S. Overexpression of VEGF-A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer. Acta Physiol (Oxf) 2006; 187:447-57. [PMID: 16866776].
59. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435-9. [PMID: 8602241].